Covid 19 Part XXVIII- 71,942 ROI(2,050 deaths) 51,824 NI (983 deaths) (28/11) Read OP

Please see the data from Pfizer.. and don't read incorrect interpretations from newspapers..

its not 94 from 43k - as over 10k haven't received their second shot yet....

Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” said Dr. Albert Bourla, Pfizer Chairman and CEO. “We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen. With today’s news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis. We look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks.”After discussion with the FDA, the companies recently elected to drop the 32-case interim analysis and conduct the first interim analysis at a minimum of 62 cases. Upon the conclusion of those discussions, the evaluable case count reached 94 and the DMC performed its first analysis on all cases. The case split between vaccinated individuals and those who received the placebo indicates a vaccine efficacy rate above 90%, at 7 days after the second dose. This means that protection is achieved 28 days after the initiation of the vaccination, which consists of a 2-dose schedule. As the study continues, the final vaccine efficacy percentage may vary. The DMC has not reported any serious safety concerns and recommends that the study continue to collect additional safety and efficacy data as planned. The data will be discussed with regulatory authorities worldwide.

“I want to thank the thousands of people who volunteered to participate in the clinical trial, our academic collaborators and investigators at the study sites, and our colleagues and collaborators around the world who are dedicating their time to this crucial endeavor,” added Bourla. “We could not have come this far without the tremendous commitment of everyone involved.”

“The first interim analysis of our global Phase 3 study provides evidence that a vaccine may effectively prevent COVID-19. This is a victory for innovation, science and a global collaborative effort,” said Prof. Ugur Sahin, BioNTech co-founder and CEO. “When we embarked on this journey 10 months ago this is what we aspired to achieve. Especially today, while we are all in the midst of a second wave and many of us in lockdown, we appreciate even more how important this milestone is on our path towards ending this pandemic and for all of us to regain a sense of normality. We will continue to collect further data as the trial continues to enroll for a final analysis planned when a total of 164 confirmed COVID-19 cases have accrued. I would like to thank everyone who has contributed to make this important achievement possible.”

The Phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,538 participants to date, 38,955 of whom have received a second dose of the vaccine candidate as of November 8, 2020. Approximately 42% of global participants and 30% of U.S. participants have racially and ethnically diverse backgrounds. The trial is continuing to enroll and is expected to continue through the final analysis when a total of 164 confirmed COVID-19 cases have accrued. The study also will evaluate the potential for the vaccine candidate to provide protection against COVID-19 in those who have had prior exposure to SARS-CoV-2, as well as vaccine prevention against severe COVID-19 disease. In addition to the primary efficacy endpoints evaluating confirmed COVID-19 cases accruing from 7 days after the second dose, the final analysis now will include, with the approval of the FDA, new secondary endpoints evaluating efficacy based on cases accruing 14 days after the second dose as well. The companies believe that the addition of these secondary endpoints will help align data across all COVID-19 vaccine studies and allow for cross-trial learnings and comparisons between these novel vaccine platforms. The companies have posted an updated version of the study protocol at https://www.pfizer.com/science/coronavirus.

I always post this video when there’s vaccine news. Rollout is ready to go, including cold storage.

lemonTrees wrote: »

It surely is. I would have been happy enough with a 70% success rate but 90% is actually astounding.

I don't think anyone expected that, really has taken the science community by surprise from what I can see online

froog wrote: »

really great news. 90% is amazing.

i see team trump trying to take credit even though pfizer was not part of operation warp speed or whatever it's called.

Yup expected nothing less from them. Pfizer always distanced themselves from them

https://twitter.com/vincekearney/status/1325801006844743682

snotboogie wrote: »

:eek:

0.06%

Stheno wrote: »

Wtf is going on up there

They must be just going around spitting in each other's faces,
Do they greet each other like in that scene in ace ventura when he goes to the village chief.

Is this what they pumped Trump with a few weeks ago? in and out of hospital in a day da kunt

wadacrack wrote: »

https://twitter.com/vincekearney/status/1325801006844743682

And they are in lockdown how long now?

Northern Irish must be showing almost total disregard for restrictions, 470 is pretty much a low point of their new cases for them lately and it's still proportionally far above anything we reported before going to level 5

sonofenoch wrote: »

Is this what they pumped Trump with a few weeks ago? in and out of hospital in a day...

No, he got Regeneron among other things , which is a trial treatment, not a vaccine .